Baar, Switzerland — September 5, 2026
Evinova announced a strategic partnership with Lothar Medical to modernize the execution of respiratory clinical trials globally by integrating Evinova’s Unified Trial Solution with Lothar Medical’s respiratory diagnostic devices. The collaboration is designed to create a more connected and data-rich clinical trial experience for sponsors, research sites, and patients involved in studies of respiratory diseases. Evinova’s globally scaled, GxP-validated digital platform supports traditional, hybrid, and decentralized clinical trials (DCTs) and is currently used by more than 4,000 sites across 54 countries. Through the partnership, respiratory diagnostic data generated through Lothar Medical’s devices can be integrated into a broader digital clinical development environment, potentially helping research teams streamline workflows and improve access to high-quality clinical data.
Evinova Integrates Respiratory Diagnostics into Trial Platform
Lothar Medical develops respiratory diagnostic technology that combines fractional exhaled nitric oxide (FeNO), spirometry, and oscillometry within a single device. The integrated approach is intended to provide real-time pulmonary function testing for both clinical research and healthcare settings. For respiratory clinical development teams working on complex studies involving asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and interstitial lung disease (ILD), combining multiple respiratory measurements in one device could simplify patient screening and clinical trial workflows. The companies expect the integration to support more efficient identification of potentially eligible participants, particularly where real-world diagnosis and clinical trial eligibility criteria do not always align. The partnership also aims to reduce fragmentation between respiratory diagnostic data and clinical trial systems, creating a more connected pathway for capturing and managing information throughout study execution.
Partnership Targets Data Quality and Operational Efficiency
The collaboration is also focused on improving the capture of clinical endpoints and diagnostic measurements during respiratory studies. Lothar Medical’s technology can generate measurements including FEV1, PEF, FeNO, airway resistance, and reactance, while Evinova’s digital infrastructure can support the integration and management of clinical trial data and patient-generated information such as symptom diaries. The companies believe this approach could reduce data silos and provide clinical development teams with higher-fidelity information for primary, secondary, and exploratory endpoints. A three-in-one respiratory device may also reduce the number of devices and separate workflows required at clinical sites and by patients. In addition, digital coaching and automated validation checks incorporated into the interface are intended to support correct device use and improve the quality and consistency of collected measurements. These capabilities could help reduce operational burden while supporting more efficient execution of increasingly complex respiratory clinical trials.
Advertisement
Evinova and Lothar Medical Target Personalized Respiratory Care
The strategic partnership represents a broader effort by Evinova and Lothar Medical to combine digital clinical development capabilities with advanced respiratory diagnostics. David Markus Thomas, Managing Director of Lothar Medical, said the collaboration could make clinical research more efficient, patient-focused, and data-driven, while supporting the development of personalized respiratory care. Evinova executives similarly highlighted the potential to combine respiratory diagnostics with digital trial capabilities to improve how studies are delivered. Evinova operates as a health technology company within the AstraZeneca group, providing AI-native and digital solutions across the clinical development lifecycle. Lothar Medical’s ALDS Ambulatory Lung Health System and ALDS PRO combine spirometry, oscillometry, and FeNO measurement in a portable point-of-care platform. The devices are CE-marked, MHRA Class IIa registered, and ISO 13485 certified. By bringing these capabilities together, the companies aim to advance digitally enabled respiratory clinical trials and support the development of more personalized approaches to respiratory disease diagnosis and treatment.
Source: Evinova press relese
